




ATTORNEY DOCKET APPLICATION NO. INFORMATION DISCLOSURE STATEMENT (37 C.F.R. 1.56, 1.97, and 1.98) 23164-1003 08/853,292 APPLICANT(S) Tovey, Michael G. FILING DATE SHEET 1 OF 2 **GROUP** May 9, 1997 1801 1646. **U.S. PATENT DOCUMENTS** t EX'R U.S. CLASS/ FILING DATE REF. # INITIAL PATENT NUMBER DATE (MO/YR) NAME **SUBCLASS** (If appropriate) Α 4,605,555 8/86 Sato et al 424/85 В 4,820,514 4/89 Cummins 424/85.4 C 5,019,382 5/91 Cummins, Jr. 424/85.4 D 5,215,741 6/93 Young et al. 424/85.7 Ε 5,286,748 2/94 Eby, III 514/494 FOREIGN PATENT DOCUMENTS † EX'R TRANSLATION INITIAL REF. # (YES/NO) F CA 1,320,905 8/93 Canada yes OTHER DOCUMENTS † EX'R INITIAL REF. # CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.) Boguniewicz et al., "The Effect of Nebulized Recombinant Interferon-γ in Asthmatic Airways", J. Allergy Clin. Immunol. 95:133-135 (1995). Brod et al., "Oral Administration of IFN- α is Superior to Subcutaneous Administration of IFN- α in the Н Suppression of Chronic...", Journal of Autoimmunity 9:11-20 (1996). Douglas et al., "Prophylactic Efficacy of Intranasal Alpha,-Interferon Against Rhinovirus Infections in the Family Setting" 314: 65-70 (1986). Hayden et al., "Intranasal Interferon $\alpha 2$ for Prevention of Rhinovirus Infection and Illness", Journal of Infectious Diseases 148:543-550 (1983). Hayden et al., "Human Tolerance and Histopathologic Effects of Long Term Administration of Intranasal Interferon- α 2", Journal of Infectious Diseases 148:914-921 (1983). Hayden et al., "Prevention of Natural colds by Contact Prophylaxis with Intranasal Alpha₂-Interferon", New England Journal Of Medicine 314:71-75 (1986). Hayden et al., "Human Nasal Mucosal Responses to Topically Applied Recombinant Leukocyte A М Interferon", Journal of Infectious Diseases 156:64-72 (1987). lida et al., "Protective Activity of Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) infections in mice", Vaccine 7:229-233 (1989). Matsuzawa et al., "Protective Effect of Mucosal Administration of Recombinant Human Macrophage Colony-Stimulating Factor...", Vaccine 15:85-89 (1997). Moore et al., "Inflammatory Markers in Bronchoalveolar Lavage Fluid of Standardbred Racehorses with Inflammatory...", Equine Veterinary Journal 29:142-147 (1997). Oehling et al., "Suppresion of the Immune System by Oral Glucocorticoid Therapy in Bronchial Asthma", Alleray 52:144-154.

> DAVID L. FITZGERALD PRIMARY EXAMINER 9/24/58 **GROUP 1800**





M	R_/	Samo et al., "Efficacy and Tolerance of Normal Volunteers", Journal of Infection	f Intranasally Applied Recombinant Leukocyte A Interferon in ous Diseases 148:535-542 (1983).
	Samo et al., "Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers. II.", Journ of Infectious Diseases 150:181-188 (1984).		
	Т	Soos et al., Oral Feeding of Interferon τ Can Prevent the Acute and Chronic Relapsing Forms of Experimental Allergic Encephalomyelitis", <i>Journal of Neuroimmunology</i> 75 :43-50 (1997).	
	U /	Vriesendorp et al., "Oral Administration of Type I Interferon Modulates the Course of Experimental Allergic Neuritis", Autoimmunity 24:157-165 (1996).	
*	٧ ,	Zielinska et al., "Comparison of the Long-Term Effects of Treatment with Oral and Parenteral", Archivum Immunologiae et Therapiae Experimentalis 44:359-366 (1996).	
DAVID L. FITZGERALD PRIMARY EXAMINER GROUP 1800			DATE CONSIDERED 9/24/58

conformance and not considered. Include copy of this form in next communication to applicant.

